whether or not the patients had diabetes and compared the incidence of cardiac events occurring over a 3-year period between treatment with nifedipine retard and angiotensin converting enzyme (ACE) inhibitor.
Introduction
In patients with hypertension complicated by diabetes, strict management of blood pressure is useful in preventing cerebrovascular accidents, coronary artery disease, and the onset and progression of vascular complications such as retinopathy and nephropathy. Guidelines from the American Diabetes Association (ADA) recommend that systolic blood pressure (SBP) be maintained below 130 mmHg and diastolic blood pressure (DBP) below 80 mmHg (1) . Those guidelines, which in the past have designated renin angiotensin system (RAS) inhibitors, β-blockers, and diuretics as drugs of first choice for antihypertensive therapy, have recently been revised to include the use of long-acting calcium-channel blockers as drugs of first choice in these applications (2) . These changes are a result of findings from largescale randomized studies, including the Syst-Eur (3), INSIGHT (subgroup analysis) (4) , and ALLHAT (5) studies, on the efficacy of long-acting calcium-channel blockers in reducing the incidence of cardiovascular events in diabetic patients. However, secondary results from the ABCD (6, 7) and FACET (8) trials have raised questions regarding the efficacy of the calcium-channel blockers. These calcium-channel blockers are no longer positioned among the drugs of first choice in the most recently published guidelines from the American College of Physicians (9) , and the use of calcium-channel blockers in the treatment of diabetic patients is currently controversial in the United States.
In Japan, calcium-channel blockers are commonly prescribed as antihypertensive agents, and are widely used in the treatment of hypertensive patients with diabetes. To date, however, there have been no large-scale outcome trials examining how effectively these drugs decrease the incidence of cardiovascular events within this high-risk population in Japan. We have already reported that the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) study showed nifedipine retard to be as effective as angiotensin converting enzyme (ACE) inhibitors in reducing the incidence of cardiac events (10) in hypertensive patients with coronary artery disease (CAD). In the present study we applied the JMIC-B subgroup analysis, categorizing patients enrolled in the JMIC-B study according to whether or not they had diabetes. We then compared the effects of nifedipine retard and ACE inhibitors on the incidence of cardiac events in each of these groups.
Methods
The JMIC-B study design has been reported previously (10) , and details are not repeated here. Briefly, the objective of the study was to compare the effects of nifedipine retard and ACE inhibitors on long-term prognosis in hypertensive patients with CAD. Coronary artery disease was defined according to the criteria of the American Heart Association as 75% stenosis on coronary arteriography (CAG) performed within 1 year prior to the study. Patients who did not undergo CAG were eligible for enrollment if findings from the patient anamnesis and examination, exercise ECG, and myocardial scintigraphy resulted in a diagnosis of myocardial ischemia. Criteria for hypertension at the time of enrollment were systolic blood pressure (SBP) 160 mmHg or diastolic blood pressure (DBP) 95 mmHg, and SBP 150 mmHg and DBP 90 mmHg. Hypertensive patients who had been previously treated with any antihypertensive drug were also eligible for enrollment. All patients were randomized to 3 years of treatment with either nifedipine retard (a long-acting nifedipine formulation that is given at a dose of 20-40 mg/day in Japan) or an ACE inhibitor (enalapril 5-10 mg/day, imidapril 5-10 mg/day, or lisinopril 10-20 mg/day as recommended in Japan) and followed up. The treatment target was blood pressure below 150/90 mmHg. If blood pressure reduction was unsatisfactory, concomitant treatment with a drug other than the study drug, such as an α-blocker or β-blocker, was permitted. If the antianginal effect was unsatisfactory, the concomitant use of long-acting or short-acting nitrates and/or β-blockers was permitted.
The primary endpoint of the study was the overall incidence of cardiac events, defined as 1) cardiac death or sudden death; 2) myocardial infarction (initial and recurrent); 3) angina pectoris requiring hospitalization; 4) heart failure requiring hospitalization; 5) serious arrhythmia (ventricular tachycardia, ventricular fibrillation); or 6) performance of coronary interventions. The secondary endpoints were cerebrovascular accidents, worsening of renal dysfunction, noncardiovascular events such as cancer, and total mortality. Blood pressure and heart rate were monitored during the observation period and at 6-month intervals after the start of treatment. Findings were expressed as mean values. Diabetes was assessed by the attending physician before treatment was initiated, with reference to World Health Organization criteria (presence of any of the following: history of diabetes, use of antidiabetes medication, or fasting blood glucose 140 mg/dl [7.8 mmol/l]) (11) and HbA1c values ( 6.5%).
In the original the JMIC-B study, the primary endpoint was the incidence of cardiac events, with patients randomly allocated into treatment groups (10) . Statistical analysis was applied to data from all patients on an intention-to-treat basis. The present study utilizes subgroup analysis by dividing data from the JMIC-B patients into diabetic and nondiabetic categories. This analysis uses relative risk and 95% confidence intervals to compare the results of the nifedipine group with the ACE inhibitor group in diabetic and nondiabetic patients. The Kaplan-Meier method was used to estimate the cumulative rates of cardiac events and other endpoints. The log-rank test was applied to assess the effects of treatment on the incidence of cardiac events. The Cox proportional hazard model was used to estimate relative risk and 95% confidence interval (CI) after adjusting for demographic variables such as sex, age, and other important covariates. A paired t-test was used for comparison of data on blood pressure, heart rate, fasting blood glucose, and HbA1c, and an unpaired ttest was used for comparison between treatment groups. Mean values for data were expressed as the mean SD. All statistical analyses were performed using SAS software, version 6.14 (SAS Institute Inc., Cary, USA).
Results

Baseline Characteristics
Of the 1,650 patients analyzed in the JMIC-B study, 372 (23%) were diabetic at treatment baseline. Table 1 shows the baseline characteristics for diabetic and nondiabetic patients in each treatment group. Except for an imbalance in the history of myocardial infarction among diabetic patients and an imbalance in the presence of angina pectoris among nondiabetic patients, no significant difference in patient characteristics was noted between the nifedipine and ACE inhibitor groups.
The incidence of silent myocardial ischemia is generally expected to be high in diabetic patients. In our present study, however, no difference in the incidence was observed between the diabetic and nondiabetic groups of the enrolled patients. Eighty-eight percent of the enrolled patients with coronary artery disease were symptomatic. In the remaining 12%, silent myocardial ischemia was diagnosed comprehensively by an individual investigator, based on the existence of chest pain, findings by exercise tolerance ECG, detection of myocardial ischemia with 201 Tl myocardial scintigraphy and so on. We consider that the criteria were appropriate.
At the time of enrollment in this study, 92% of patients (1,515/1,650) had been previously treated for hypertension. The remaining 8% (135/1,650) were untreated hypertensive patients. Among diabetic patients, baseline SBP and DBP were 147/82 mmHg in the nifedipine group and 146/81 mmHg in the ACE inhibitor group, while among nondiabetic patients these figures were 147/82 mmHg and 145/82 mmHg, respectively. No significant difference was observed between the two treatment groups in patients with or without diabetes. In diabetic patients, fasting blood glucose values and HbA1c showed no significant differences between the nifedipine group (154 mg/dl [8.5 mmol/l] and 7.2%) and the ACE inhibitor group (146 mg/dl [8.0 mmol/l] and 7.2%). Table 2 shows the breakdown of patients by severity of diabetes, based on the blood glucose control criteria ("Diabetes Treatment Guide 2002-2003" by Japan Diabetes Society (12)). As can be seen, "controllable diabetes" with an HbA1c of less than 8.0% (excellent, good, and fair) accounted for 75% of the total diabetic patients, and this distribution indicated that there was no statistically significant deviation between the drug groups. Blood Pressure, Heart Rate, and Blood Glucose Figure 1 shows changes for blood pressure and heart rate during treatment. Findings in both the nifedipine group and the ACE inhibitor group showed significant reductions in SBP and DBP after 6 months of treatment in comparison to baseline in patients with diabetes ( Fig. 1a ) and in those without diabetes (Fig. 1b) (Table 3 ) among diabetic patients were 138/76 mmHg in the nifedipine group and 140/78 mmHg in the ACE inhibitor group, with no significant difference between these two groups. In the nondiabetic group, mean achieved blood pressure was 136/77 mmHg in the nifedipine group and 138/79 mmHg in the ACE inhibitor group, with nifedipine use associated with significantly lower values for both SBP and DBP (unpaired t-test, p< 0.01). Among diabetic patients, there was no significant difference in the incidence of concomitant use of other antihypertensives during the treatment period: 9.1% and 9.8% for α-blockers; 27.1% and 23.1% for β-blockers; and 9.1% and 9.8% for diuretics in the nifedipine group and ACE inhibitor group, respectively. Among nondiabetic patients there was significantly less concomitant use of α-blockers in the nifedipine group than in the ACE inhibitor group (5.4% and 10.9%, p< 0.01). However, this difference in the rate of the α-blocker use had no significant influence on the incidence of cardiac events. The rate of concomitant use of β-blockers was 24.1% and 23.4%; and for diuretics, 7.5% and 9.2% in the nifedipine group and ACE inhibitor group, respectively, with no significant difference observed between the two groups. No significant changes in heart rate were observed in either treatment group, among either diabetic or nondiabetic patients, throughout the duration of the treatment period. Among diabetic patients, no significant changes in fasting blood glucose level and HbA1c were observed 36 months af- 
Outcomes in Diabetic and Nondiabetic Patients
Because of the statistical imbalance in patient characteristics at baseline (history of myocardial infarction in diabetic patients, and history of angina pectoris in nondiabetic patients), Follow-up: mean blood pressure and heart rate during 6 to 36 months. Change: blood pressure and heart rate difference (follow-up baseline). ACE, angiotensin converting enzyme.
Fig. 2. Incidence and relative risks and 95% confidence intervals for the primary and secondary endpoints in diabetic and nondiabetic patients.
the Cox proportional hazard model was applied to correct for these important factors as well as for age and sex. Findings for the incidence of cardiac events (primary endpoint) and cerebrovascular accidents, worsening of renal dysfunction, non-cardiovascular events, and total mortality (secondary endpoints) were compared between the nifedipine group and the ACE inhibitor group in patients with or without diabetes at treatment baseline (Fig. 2) . We found no significant difference between the nifedipine group and the ACE inhibitor group in the incidence of cardiac events in diabetic patients (15.08% vs. 15.03%, relative risk 1.06; 95% CI, 0.61 to 1.84; p 0.838). We also found no significant difference between the two treatment groups with regard to the occurrence of secondary endpoints (5.03% vs. 5.20%, relative risk 0.89; 95% CI, 0.35 to 2.25; p 0.799). There was no significant difference in the Kaplan-Meier curve for the primary endpoint (log-rank test, p 0.719) or in the Kaplan-Meier curve for primary plus secondary endpoints (log-rank test, p 0.668) between the two groups during the 3 years of treatment (Fig. 3a) . Table 4 shows the relative risk for each event in diabetic patients. We found no significant difference between the two treatment groups for any of these events. A comparison of endpoints within the nondiabetic subgroup showed no significant difference between the nifedipine group and the ACE inhibitor group with regard to occurrence of the primary endpoint (13.67% vs. 12.33%, relative risk 1.04; 95% CI, 0.77 to 1.41; p 0.792) or the secondary endpoints (2.70% vs. 2.47%, relative risk 1.07; 95% CI, 0.54 to 2.13; p 0.842) (Fig. 2) . Kaplan-Meier curves also showed no significant difference between the two treatment groups with regard to primary endpoint (log-rank test, p 0.741) or primary plus secondary endpoints (log-rank test, p 0.818) (Fig. 3b) .
Discussion
In the present study we used subgroup analysis to stratify data from the JMIC-B patient population into diabetic and nondiabetic subgroups, and compared the effects of nifedipine retard and ACE inhibitors on the incidence of cardiac events. Our results showed no difference in reduction of cardiac events between the nifedipine retard group and the ACE inhibitor group among those with or without diabetes. These findings do not support the results from the ABCD (6, 7) or FACET (8) studies. The ABCD and FACET studies were not originally designed to investigate the effects of treatment on reduction of cardiovascular events, and in particular the early discontinuation of the ABCD study may have contributed to an overemphasis on risk when evaluating the study findings. Secondary conclusions drawn from these studies suggested that diabetic patients who were treated with calcium-channel blockers were at a higher risk for myocardial infarction than those treated with ACE inhibitors. However, the grounds for these conclusions were actually quite tenuous. In contrast, subgroup analysis of diabetic patients within the STOP-2 study (13) showed that treatment with calcium-channel blockers did not produce a higher incidence of the primary endpoint (occurrence of cardiovascular events) than did treatment with ACE inhibitors in this patient population. A recently reported subgroup analysis from the INSIGHT study (4) also showed that long-acting nifedipine preparations were equivalent to diuretics in reducing cardiovascular events in diabetic patients, suggesting that long-acting nifedipine could be considered as a drug of first choice in this context. Our findings are consistent with these reported results. In hypertensive patients with complications of diabetes, stringent management of blood pressure is considered to be essential. Syst-Eur subgroup analysis (3) has been reported to indicate that antihypertensive treatment with calcium-channel blockers is more beneficial in patients with diabetes than in those without diabetes. Our results showed that in patients with complications of diabetes, blood pressure was reduced to SBP 140 mmHg or below and DBP 80 mmHg or below in both treatment groups during the 3 years of treatment. These values were lower than those in the ABCD moderate group (138/86 mmHg) (14) , the calciumchannel blocker groups in the FACET (153/86 mmHg) (8), the STOP-2 (163/82 mmHg) (13), the Syst-Eur (153/78 mmHg) (3), or the INSIGHT (138/82 mmHg) (4) studies, and were similar to the achieved blood pressure levels in the ALLHAT study (136/76 mmHg) (5). Although previous large-scale clinical trials were unable to achieve the levels recommended in the ADA guidelines for antihypertensive therapy (<130/80 mmHg) (1, 2) , results from the present study showed blood pressure to be controlled at one of the lowest levels ever reported. A comparison of achieved blood pressure levels showed a difference of several millimeters of mercury between the nifedipine and ACE inhibitor groups in both diabetic patients and nondiabetic patients. However, the results remained unchanged even after achieved blood pressure values were incorporated as a covariate in the Cox proportional hazards model and findings were corrected for relative risk of cardiac events (diabetic patients: relative risk, 1.17; 95% CI, 0.67 to 2.06; p 0.579; nondiabetic patients: relative risk,1.06; 95% CI, 0.77 to 1.45; p 0.733). In our present study, it was confirmed that the rate of smokers was significantly higher in the diabetic patients than in the nondiabetic patents. In 2001, Kato et al. (15) reported that Japanese hypertensive patients with both a smoking habit and diabetes may have a soaring risk for coronary artery disease. On the other hand, Suka et al. (16) studied the effects of risk factors for coronary artery disease in Japanese male patients, and compared their results with the results of the Framingham Study; they reported that smoking was a lower risk factor for cardiac events in Japanese than in Caucasian patients. Thus the degree of risk by smoking may differ between Japanese and Caucasians. For this reason, we cannot presently address the discrepancy between the results of our study, which included a high percentage of diabetics with a smoking habit, and the results of studies overseas.
There have been no comparative studies investigating the difference in vaso-reactivity between Caucasian and Japanese diabetics. However, in a collaborative study between institutions in Japan and Italy, Pristipino et al. reported that spasm was three times more likely to be involved in coronary disease in Japanese than in Caucasians (17) . We there- The relative risk and p values were determined by using the Cox proportional hazard model with adjustment for sex, age, and history of myocardial infarction and angina pectoris. Coronary intervention: percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, stenting. ACE, angiotensin converting enzyme; CI, confidence interval.
fore consider that the results of studies on Caucasians are not always extensible to Japanese patients. From findings in the JMIC-B study, we extracted data on patients with complications of diabetes, considered to be an extremely high-risk population, and compared the effects of nifedipine retard and ACE inhibitors on the reduction of cardiac events. Our results indicated that nifedipine retard inhibited cardiac events to a degree equivalent to that obtained with the ACE inhibitors, both in diabetic and nondiabetic patients. These findings support the results of the INSIGHT subanalysis (4) and the ALLHAT (5) findings.
One limitation of our findings is that they are the result of subanalysis of patients with complications of diabetes, and thus their statistical power is somewhat limited. Recently, the BPLTT Collaboration (18) and Staessen et al. (19) reported the results of a meta-analysis with high statistical power, which clearly showed the importance of adequately reducing blood pressure levels by means of antihypertensive agents. We look forward to the future implementation of prospective studies in high-risk populations and also to the results of meta-analyses stratified by patient age and morbidity.
